<DOC>
	<DOCNO>NCT01052272</DOCNO>
	<brief_summary>The investigator hypothesize patient diabetes acute myocardial infarction ( MI ) , Ang II type-1 receptor blockade ( AT1RB ) attenuate left ventricle ( LV ) remodel great extent angiotensin convert enzyme ( ACE ) inhibitor therapy addition xanthine oxidase ( XO ) inhibitor , Allopurinol , result improvement LV remodel function follow-up phase MI .</brief_summary>
	<brief_title>Impact Diabetes Left Ventricular Remodeling</brief_title>
	<detailed_description>Following myocardial infarction ( MI ) , incidence heart failure mortality rate approximately two-fold high patient diabetes compare without diabetes . This increase risk heart failure mortality appear refractory currently available treatment angiotensin convert enzyme ( ACE ) inhibitor , despite effectiveness treatment reduce overall morbidity mortality follow MI . Hyperglycemia stimulate cardiomyocyte angiotensin II ( Ang II ) formation , implicate increase myocyte cell death diabetes . Furthermore , human , chymase predominant pathway Ang II formation pathway Ang II production block ACE inhibition . Therefore , diabetes Ang II level may already elevate due hyperglycemia increase Ang II formation associate leave ventricular ( LV ) remodel continue Ang II formation chymase could particularly detrimental . In addition enhance Ang II production , hyperglycemia diabetes also amplify production reactive oxygen specie ( ROS ) . ROS associate increase LV remodel myocyte apoptosis . Furthermore , xanthine oxidase ( XO ) , important source ROS myocytes , increase rat model myocardial infarction diabetes . Thus , increase XO-mediated ROS production follow MI may especially damage diabetic patient ROS production already elevate . Interestingly , acute treatment Allopurinol , inhibitor XO , improve cardiac function heart failure improve endothelial dysfunction patient type-2 diabetes . To test hypothesis investigator investigate follow aim diabetic patient acute MI : Aim 1 : Show progression LV remodel dysfunction diabetic patient attenuate great extent AT1RB ACE inhibitor . Aim 2 : Show addition XO inhibition result attenuation LV remodel AT1RB ACE inhibitor alone . Aim 3 : Show baseline follow-up LV remodel dysfunction inflammatory marker differ diabetic non-diabetic patient post-MI .</detailed_description>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>1 . 21 year old old 2 . MI document increase troponin &gt; 0.78 ng/ml CKMB ≥ 3 % total CK Patients Type2 diabetes define one following : 3 . Confirmed ( i.e. , two reading ) fast blood glucose &gt; 126mg/dl ; 4 . Random glucose ≥200mg/dl ; 5 . 2 hour glucose ≥200mg/dl follow 75g glucose ; 6 . Current treatment diet oral agent direct control hyperglycemia either alone combination insulin ; 7 . Current treatment insulin prior history diabetic ketoacidosis . 1 . Type1 diabetes . 2 . Class III IV heart failure . 3 . Cardiomyopathy ( include hypertrophic amyloidosis ) . 4 . Congenital pericardial disease . 5 . Intolerance either ACE inhibitor , AT1RB allopurinol . 6 . Renal failure creatinine &gt; 2.5 mg/dl . 7 . Renal artery stenosis . 8 . Severe comorbidity liver disease malignancy . 9 . Pregnancy ( negative pregnancy test effective contraceptive method require prior enrollment female childbearing potential ( postmenopausal surgically sterilize ) . 10 . Chronic steroid use . 11 . Unable understand cooperate protocol requirement . 12 . Severe claustrophobia . 13 . Presence pacemaker nonremovable hearing aid . 14 . Presence metal clip body .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Acute MI</keyword>
	<keyword>Ang II type-1 receptor blockade ( AT1RB )</keyword>
	<keyword>LV remodel</keyword>
	<keyword>ACE inhibitor therapy</keyword>
	<keyword>XO inhibitor , Allopurinol</keyword>
	<keyword>Systolic dysfunction</keyword>
	<keyword>Diastolic dysfunction</keyword>
	<keyword>LV dimension</keyword>
	<keyword>Cardiac MRI</keyword>
</DOC>